News & Publications

Latest Updates

February 24, 2021 in All, Asclepix Therapeutics

AsclepiX Therapeutics partners with Notal Vision on Home OCT remote monitoring in DME and AMD clinical trials

The technology could set new standards for data enrichment and patient-centric conduct of clinical trials February 23, 2021 08:00 ET | Source: Notal Vision Manassas, VA, Feb. 23, 2021 (GLOBE…
Read More
February 23, 2021 in All, NexImmune

Barer & Son Capital and Hibiscus Capital Management Announce Successful Initial Public Offering of Portfolio Company NexImmune

NexImmune Raises Gross Proceeds of $126.5M in Upsized IPO after Full Exercise of Underwriters' Option to Purchase Additional Shares Feb 23, 2021, 08:00 ET ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/…
Read More
February 11, 2021 in All, NexImmune

NexImmune Announces Pricing of Upsized Initial Public Offering

GAITHERSBURG, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate…
Read More
January 18, 2021 in All, NexImmune

Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Officer

With more than 25 years of clinical development leadership experience at companies such as Celgene and Kite Pharmaceuticals, Dr. Knight will now lead the clinical development of NexImmune’s novel immunotherapy…
Read More
January 5, 2021 in All, Asclepix Therapeutics

AsclepiX Therapeutics, Inc. Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for Diabetic Macular Edema (DME)

BALTIMORE, MD, January 5, 2021 – AsclepiX Therapeutics, Inc., a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular and cellular homeostasis for the treatment of retinal and…
Read More
January 5, 2021 in All, NexImmune

NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor

Zeldis formerly served as Celgene CMO and CEO of Celgene Global HealthWeber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientistBoth will help NexImmune advance current early-stage…
Read More
December 22, 2020 in All, Cereno Scientific

Cereno Scientific terminates agreement with liquidity provider

TUE, DEC 22, 2020 16:30 CET Cereno Scientific announced today that the agreement with Mangold Fondkommission to act as liquidity provider for the company’s share has been terminated. The share…
Read More
December 7, 2020 in All, NexImmune

Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition

Initial data demonstrate early signs of safety, tolerability and robust immune responses in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic hematopoietic cell transplantation (allo-HSCT) GAITHERSBURG, Md., Dec.…
Read More
November 19, 2020 in 3DBio Therapeutics, All

3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients

NEW YORK, Nov. 19, 2019 /PRNewswire/ -- 3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced it has received Orphan Drug Designation for AuriNovo™, an investigational…
Read More
November 4, 2020 in All, NexImmune

NexImmune to Highlight Preliminary Results from Phase 1/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting

GAITHERSBURG, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that an abstract containing preliminary data from its first-in-human…
Read More
October 27, 2020 in All, NexImmune

NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia

City of Hope will combine its world-leading expertise with NexImmune technology to explore tumor escape mechanisms and to identify unique leukemia stem cell targets for next generation immunotherapeutics GAITHERSBURG, Md.,…
Read More
October 14, 2020 in All, Asclepix Therapeutics

AsclepiX Therapeutics to Present at Solebury Trout Private Company Showcase on October 15, 2020

BALTIMORE, MD, October 13, 2020 – AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular homeostasis for the treatmentof retinal and other important…
Read More
October 6, 2020 in All, NexImmune

First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma

With the start of its second clinical trial, NexImmune expands development of its unique non-genetically engineered T cell immunotherapies across a range of hematologic malignancies GAITHERSBURG, Md., Oct. 06, 2020…
Read More
October 2, 2020 in All, Cereno Scientific

Record date for distribution of warrants of series TO1 and TO2 to current shareholders is set for October 9, 2020

FRI, OCT 02, 2020 17:41 CET As previously announced, the Board of Directors of Cereno Scientific AB (”Cereno” or the ”Company”) has decided to distribute warrants of series TO1 and…
Read More
September 30, 2020 in All, Cereno Scientific

Cereno Scientific publishes interim report for Q3 2020 (1 January – 30 September 2020)

THU, NOV 19, 2020 08:33 CET The Board and Chief Executive Officer of Cereno Scientific AB here presents the interim report for the third quarter 2020. Summary of the interim report Cereno Scientific Group Year…
Read More
September 29, 2020 in All, Cereno Scientific

Cereno Scientific enters rare disease space with lead drug candidate CS1

TUE, SEP 29, 2020 17:30 CET Cereno Scientific today announced that the company will advance the development of drug candidate CS1 as an epigenetic modulator of rare diseases with orphan…
Read More
September 23, 2020 in All, NexImmune

NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)

Company is using its Artificial Immune Modulation (AIM) nanoparticle technology to develop T cell immunotherapies for patients with relapsed and/or refractory hematologic malignancies GAITHERSBURG, Md., Sept. 23, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing…
Read More
August 27, 2020 in All

Bayer and Northpond Ventures Lead USD 55 million Series A Financing Round for Triumvira Immunologics

Leaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno oncology treatments Triumvira’s T-cell therapies have transformative potential as a new type of cancer treatment…
Read More
June 24, 2020 in All, Asclepix Therapeutics

AsclepiX Therapeutics Announces $35 Million Series A Financing

Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials Series A financing led by the Perceptive Xontogeny Venture Fund BALTIMORE, MD, June 24,…
Read More
June 9, 2020 in All, Cereno Scientific

Cereno Scientific enters collaboration with University of Michigan

TUE, JUN 09, 2020 08:40 CET Cereno Scientific today announced that the company enters a collaboration agreement with the University of Michigan in Ann Arbor, USA. On behalf of Cereno…
Read More
December 22, 2020 in All, Cereno Scientific

Cereno Scientific terminates agreement with liquidity provider

TUE, DEC 22, 2020 16:30 CET Cereno Scientific announced today that the agreement with Mangold Fondkommission to act as liquidity provider for the company’s share has been terminated. The share…
Read More
October 2, 2020 in All, Cereno Scientific

Record date for distribution of warrants of series TO1 and TO2 to current shareholders is set for October 9, 2020

FRI, OCT 02, 2020 17:41 CET As previously announced, the Board of Directors of Cereno Scientific AB (”Cereno” or the ”Company”) has decided to distribute warrants of series TO1 and…
Read More
September 30, 2020 in All, Cereno Scientific

Cereno Scientific publishes interim report for Q3 2020 (1 January – 30 September 2020)

THU, NOV 19, 2020 08:33 CET The Board and Chief Executive Officer of Cereno Scientific AB here presents the interim report for the third quarter 2020. Summary of the interim report Cereno Scientific Group Year…
Read More
September 29, 2020 in All, Cereno Scientific

Cereno Scientific enters rare disease space with lead drug candidate CS1

TUE, SEP 29, 2020 17:30 CET Cereno Scientific today announced that the company will advance the development of drug candidate CS1 as an epigenetic modulator of rare diseases with orphan…
Read More
June 9, 2020 in All, Cereno Scientific

Cereno Scientific enters collaboration with University of Michigan

TUE, JUN 09, 2020 08:40 CET Cereno Scientific today announced that the company enters a collaboration agreement with the University of Michigan in Ann Arbor, USA. On behalf of Cereno…
Read More
May 14, 2020 in All, Cereno Scientific

The Board and Chief Executive Officer of Cereno Scientific AB here with present the Interim Report for the first quarter 2020

The Board and Chief Executive Officer of Cereno Scientific AB here with present the Interim Report for the first quarter 2020. Summary of the Interim Report Cereno Scientific Group  (2020-01-01…
Read More
February 23, 2021 in All, NexImmune

Barer & Son Capital and Hibiscus Capital Management Announce Successful Initial Public Offering of Portfolio Company NexImmune

NexImmune Raises Gross Proceeds of $126.5M in Upsized IPO after Full Exercise of Underwriters' Option to Purchase Additional Shares Feb 23, 2021, 08:00 ET ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/…
Read More
February 11, 2021 in All, NexImmune

NexImmune Announces Pricing of Upsized Initial Public Offering

GAITHERSBURG, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate…
Read More
January 18, 2021 in All, NexImmune

Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Officer

With more than 25 years of clinical development leadership experience at companies such as Celgene and Kite Pharmaceuticals, Dr. Knight will now lead the clinical development of NexImmune’s novel immunotherapy…
Read More
January 5, 2021 in All, NexImmune

NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor

Zeldis formerly served as Celgene CMO and CEO of Celgene Global HealthWeber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientistBoth will help NexImmune advance current early-stage…
Read More
December 7, 2020 in All, NexImmune

Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition

Initial data demonstrate early signs of safety, tolerability and robust immune responses in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic hematopoietic cell transplantation (allo-HSCT) GAITHERSBURG, Md., Dec.…
Read More
November 4, 2020 in All, NexImmune

NexImmune to Highlight Preliminary Results from Phase 1/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting

GAITHERSBURG, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that an abstract containing preliminary data from its first-in-human…
Read More
February 24, 2021 in All, Asclepix Therapeutics

AsclepiX Therapeutics partners with Notal Vision on Home OCT remote monitoring in DME and AMD clinical trials

The technology could set new standards for data enrichment and patient-centric conduct of clinical trials February 23, 2021 08:00 ET | Source: Notal Vision Manassas, VA, Feb. 23, 2021 (GLOBE…
Read More
January 5, 2021 in All, Asclepix Therapeutics

AsclepiX Therapeutics, Inc. Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for Diabetic Macular Edema (DME)

BALTIMORE, MD, January 5, 2021 – AsclepiX Therapeutics, Inc., a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular and cellular homeostasis for the treatment of retinal and…
Read More
October 14, 2020 in All, Asclepix Therapeutics

AsclepiX Therapeutics to Present at Solebury Trout Private Company Showcase on October 15, 2020

BALTIMORE, MD, October 13, 2020 – AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular homeostasis for the treatmentof retinal and other important…
Read More
June 24, 2020 in All, Asclepix Therapeutics

AsclepiX Therapeutics Announces $35 Million Series A Financing

Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials Series A financing led by the Perceptive Xontogeny Venture Fund BALTIMORE, MD, June 24,…
Read More
January 6, 2020 in All, Asclepix Therapeutics

AsclepiX Therapeutics, Inc. Expands Leadership Team with Appointment of Industry Leader Theresa Heah, MD, MBA as Chief Medical Officer

BALTIMORE, MD – AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular and cellular homeostasis for the treatment of retinal and other…
Read More
November 19, 2020 in 3DBio Therapeutics, All

3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients

NEW YORK, Nov. 19, 2019 /PRNewswire/ -- 3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced it has received Orphan Drug Designation for AuriNovo™, an investigational…
Read More
December 6, 2019 in 3DBio Therapeutics, All

3DBio Therapeutics Receives FDA Rare Pediatric Disease Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients

NEW YORK, December 6, 2019 /PRNewswire/ — 3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted…
Read More
April 2, 2019 in 3DBio Therapeutics, All

3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors

NEW YORK, April 2, 2019 /PRNewswire/ -- 3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced the appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to…
Read More